Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Single-Arm Phase II Study of MOR208 Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: L-Mind

Gilles Andre Salles, MD PhD, Johannes Duell, MD, Eva González-Barca, MD PhD, Wojciech Jurczak, PhDMD, Anna Marina Liberati, MD, Zsolt Nagy, MD PhD, Tomáš Papajik, MD PhD, Gianluca Gaidano, MD PhD, Marc Andre, MD, Nagesh Kalakonda, MD, Martin Dreyling, MD PhD, Pier Luigi Zinzani, MD, Sumeet Ambarkhane, MD, Johannes Weirather, PhD, Maren Dirnberger-Hertweck, PhD, Kami J. Maddocks, MD

Blood (2017) 130 (Supplement 1): 4123.

https://doi.org/10.1182/blood.V130.Suppl_1.4123.4123

Published: 2017

Journal Articles

Gender, Age and TP53 Aberrations in Context of Complex Karyotypes in Chronic Lymphocytic Leukemia Patients in the Era of Chemo +/- Immunotherapy

Lenka Kruzova, MA, Petra Schneiderova, Milena Holzerova, Michaela Vatolikova, Martina Divoka, Peter Turcsanyi, Renata Urbanova, Milos Kudelka, Martin Radvansky, Eva Kriegova, Tomas Papajik, MD PhD, Helena Urbankova, MSc, PhD

Blood (2017) 130 (Supplement 1): 2991.

https://doi.org/10.1182/blood.V130.Suppl_1.2991.2991

Published: 2017

Journal Articles

Rituximab Maintenance Failure in Mantle Cell Lymphoma Is Associated with High Risk of Death: Analysis of the Czech Lymphoma Study Group (CLSG)

Aleš Obr, MD, Vit Prochazka, MD PhD Assoc Prof, Tomas Papajik, MD PhD prof., Pavel Klener, Jr., MD PhD Assoc Prof, Andrea Janikova, MD PhD Assoc Prof, David Salek, MD PhD, David Belada, MD PhD, Robert Pytlik, Alice Sýkorová, MD PhD, Heidi Mocikova, MD PhD, Martin Simkovic, MD PhD, Vit Campr, MD PhD, Jitka Dlouha, Tomas Fuerst, MSc, PhD, Marek Trněný, MD PhD

Blood (2017) 130 (Supplement 1): 1498.

https://doi.org/10.1182/blood.V130.Suppl_1.1498.1498

Published: 2017

Journal Articles

Low Hodgkin/Reed-Sternberg Cell Density Assessed with Automated Image Analysis Is a Poor Prognostic Factor in Classic Hodgkin Lymphoma Patients

Vit Prochazka, MD PhD ass. prof., Tereza Dyskova, Dr., Zuzana Prouzova, MD, Tomas Papajik, MD PhD prof., Jiri Minarik, MD PhD, Juraj Duras, MD, Jozef Michalka, MD, Alice Sykorova, MD PhD, Peter Mikula, MD, Ludek Raida, MD PhD, Eva Kriegova, Dr., PhD

Blood (2015) 126 (23): 4999.

https://doi.org/10.1182/blood.V126.23.4999.4999

Published: 2015

Journal Articles

Impact Of Rituximab Maintenance Schedule On Prognosis In First Line Treatment Of Follicular Lymphoma. Retrospective Analysis From Czech Lymphoma Group (CLG) Database

Andrea Janikova, MD, PhD, Zbynek Bortlicek, Vit Campr, MD, Ph.D., Leos Kren, MD, PhD, David Belada, M.D., Ph.D., Vit Prochazka, M.D., Ph.D., Robert Pytlik, MD, Ph.D., Jan Pirnos, MD, Milan Matuska, MD, PhD, Tomas Papajik, MD, PhD, ass. prof., Heidi Mocikova, MD, PhD, Samuel Vokurka, MD, PhD, Jiri Mayer, MD, PhD, Marek Trneny, MD, Ph.D., Prof.

Blood (2013) 122 (21): 4387.

https://doi.org/10.1182/blood.V122.21.4387.4387

Published: 2013

Journal Articles

Frontline Intensive Chemotherapy Brings Survival Benefit In Young, Risky Patients With Follicular Lymphoma: Pair-Matched Analysis From The Czech Lymphoma Study Group (CLSG) Database

Vit Prochazka, M.D., Ph.D., Marek Trneny, MD, Ph.D., Prof., Andrea Janikova, MD, PhD, David Belada, M.D., Ph.D., Tomas Kozak, M.D., Ph.D., ass. prof., Tomas Papajik, MD, PhD, ass. prof., Vit Campr, MD, Ph.D., David Salek, MD, Ph.D., Robert Pytlik, MD, Ph.D., Alice Sykorova, MD, PhD, Milada Jankovska, MD, Jitka Dlouha

Blood (2013) 122 (21): 4354.

https://doi.org/10.1182/blood.V122.21.4354.4354

Published: 2013

Journal Articles

The Rituximab Treament for Relapsed Follicular Lymphomas Changes the Duration of Subsequent Responses. the Analysis on Behalf of CLSG

Marek Trneny, MD, PhD, Robert Pytlik, MD, David Belada, MD, PhD., Katerina Kubackova, MD, Milada Jankovska, MD, Tomas Papajik, MD., PhD., Jan Pirnos, MD, Hana Krejcova

Blood (2008) 112 (11): 1014.

https://doi.org/10.1182/blood.V112.11.1014.1014

Published: 2008

Journal Articles

Mantle Cell Lymphoma International Prognostic Score Is Valid and Confirmed in Unselected Cohort of Patients Treated in Rituximab Era

David Salek, MD, Ingrid Vasova, MD, Robert Pytlik, MD, David Belada, MD, PhD, Tomas Papajik, MD, PhD, Katerina Kubackova, MD, Jan Pirnos, MD, Ludmila Boudova, MD, PhD, Roman Kodet, MD, Petra Obrtlikova, MD, Hana Krejcova, Marek Trneny, MD, PhD

Blood (2008) 112 (11): 3745.

https://doi.org/10.1182/blood.V112.11.3745.3745

Published: 2008

NARROW

Single-Arm Phase II Study of MOR208 Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: L-Mind

Gender, Age and TP53 Aberrations in Context of Complex Karyotypes in Chronic Lymphocytic Leukemia Patients in the Era of Chemo +/- Immunotherapy

Rituximab Maintenance Failure in Mantle Cell Lymphoma Is Associated with High Risk of Death: Analysis of the Czech Lymphoma Study Group (CLSG)

Low Hodgkin/Reed-Sternberg Cell Density Assessed with Automated Image Analysis Is a Poor Prognostic Factor in Classic Hodgkin Lymphoma Patients

Impact Of Rituximab Maintenance Schedule On Prognosis In First Line Treatment Of Follicular Lymphoma. Retrospective Analysis From Czech Lymphoma Group (CLG) Database

Frontline Intensive Chemotherapy Brings Survival Benefit In Young, Risky Patients With Follicular Lymphoma: Pair-Matched Analysis From The Czech Lymphoma Study Group (CLSG) Database

The Rituximab Treament for Relapsed Follicular Lymphomas Changes the Duration of Subsequent Responses. the Analysis on Behalf of CLSG

Mantle Cell Lymphoma International Prognostic Score Is Valid and Confirmed in Unselected Cohort of Patients Treated in Rituximab Era

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only